1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Alpa Laboratories Limited

Alpa Laboratories Limited

52.00
INR
+1.50
(+2.97%)
2.07EPS
32.88P/E
1.43BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
26.95
27.1
25.44
29.72
29.42
36.32
40.34
45.82
52.52
43.92
51.29
53.06
49.9
52.25
Basic EPS, GAAP
-2.45
-0.66
3.25
1.2
1.33
0.48
0.88
3.44
6.7
5.98
7.97
9.27
7.13
2.07
Free Cash Flow per Basic Share
2.79
-1.42
-15.41
7.4
-7.94
-0.88
7.24
-2.34
3.68
3.7
1.73
3.3
2.87
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
41.97
41.14
43.82
45.02
46.36
46.81
47.7
51.16
57.86
63.96
72.2
81.48
88.53
- -
Tangible Book Value per Share
41.97
41.14
39.98
42.14
44.44
45.85
47.7
51.13
57.81
63.92
72.17
81.45
88.52
- -
Basic Weighted Avg Shares
21
21
21
21
21
21
21
21
21
21
21
21
21
21
Sales/Revenue/Turnover
567
574
536
625
619
764
849
964
1,105
924
1,079
1,116
1,050
1,106
Operating Margin (%)
-5.97
-3.19
15.52
9.05
3.44
-0.6
5.33
10.08
8.63
7.95
7.22
3.09
1.68
-3.03
Depreciation Expense
91
61
8
28
31
31
32
12
17
13
20
22
21
23
Net Income, GAAP
-52
-14
68
25
28
10
19
72
141
126
168
195
150
44
Effective Tax Rate (%)
- -
- -
29.69
55.32
39.51
63.29
36.25
32.81
27.96
20.81
18.88
24.01
10.11
25.91
Profit Margin (%)
-9.09
-2.44
12.77
4.03
4.53
1.32
2.18
7.52
12.75
13.62
15.55
17.47
14.3
3.96
Working Capital
205
714
754
749
744
718
747
884
1,066
1,167
1,329
1,458
1,584
- -
LT Debt
42
- -
- -
5
6
4
2
- -
21
8
- -
- -
- -
- -
Total Equity
883
866
922
947
975
985
1,004
1,076
1,217
1,346
1,519
1,714
1,863
- -
Return on Invested Capital (%)
- -
- -
3.65
0.95
0.74
-0.64
1.69
4.74
5.44
3.96
4.04
1.18
0.62
- -
Return on Capital (%)
- -
- -
6.69
2.93
3.14
1.17
1.91
6.96
12.04
9.57
11.59
11.88
8.34
- -
Return on Common Equity (%)
-5.67
-1.6
7.66
2.7
2.92
1.03
1.86
6.97
12.29
9.82
11.71
12.06
8.39
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
25
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
1,628
973
1,431

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,109
- -
Cash, Cash Equivalents & STI
- -
1,379
- -
Accounts Receivable, Net
- -
408
- -
Inventories
- -
133
- -
Total Current Liabilities
- -
525
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
25
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.39%
11.61%
8.66%
Free Cash Flow
-172.93%
-46.59%
-12.9%
Net Income, GAAP
36.87%
22.06%
-23.04%
Sales/Revenue/Turnover
7.63%
2.5%
-5.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
214
249
262
399
1,116
2026
191
263
290
314
1,050
2027
239
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.42
3.66
4.23
-0.95
9.27
2026
5.59
0.05
0.9
0.66
7.13
2027
0.49
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Paresh Chawla
Full Time Employees
457
Sector
Health technology
Industry
Pharmaceuticals: major
Address
33/2 Pigdamber Indore MP India 453446
IPO Date
Jul 12, 2007
Website
alpalabs.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Alpa Laboratories Limited manufactures and sells pharmaceutical finished dosage forms in India. The company produces a wide range of ethical, generic, and over-the-counter (OTC) drugs for human and veterinary use, including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams, and gels; its product portfolio covers therapeutic categories such as anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics, anti-inflammatory drugs, cough and cold preparations, cardiovascular drugs, anti-diabetics, nutritional supplements, psychotropic drugs, skin care preparations, and ear and eye care products. Alpa Laboratories operates WHO-GMP and ISO 9001:2000 certified manufacturing facilities at Pigdamber, near Indore, Madhya Pradesh, spanning 1.20 acres with dedicated production areas designed for high output and quality; it sells products under its own brands through distributors, retail chemists, pharmacy stores, and hospitals, while also serving as a contract manufacturer for Indian and multinational companies. Founded in 1967 and headquartered in Indore, India, the company exports to South and Central America, Africa, Asia, Russia, Ukraine, Kazakhstan, and other international markets. In recent developments, Alpa Laboratories announced the acquisition of land at Pithampur for expansion; appointed Ms. Srashti Chopra as Company Secretary and Compliance Officer; changed the designation of Mr. Vitthal Kothana from Non-Executive to Executive Director; and reported consolidated financial results for quarters ended December 2024, September 2024, June 2025, and the full year ended March 31, 2025, alongside multiple disclosures under SEBI (SAST) Regulations for share acquisitions by promoters and related parties.